1 Title

- 2 The differential regulation of placenta trophoblast bisphosphoglycerate mutase in fetal growth
- 3 restriction: preclinical study in mice and observational histological study of human placenta.
- 4
- 5

6 Authors

- 7 Sima Stroganov¹, Talia Harris¹, Liat Fellus-Alyagor¹, Lital Ben Moyal¹, Romina Plitman Mayo¹, Ofra
- 8 Golani¹, Alexander Brandis¹, Tevie Mehlman¹, Michal Kovo², Tal Biron-Shental², Nava Dekel¹,
- 9 Michal Neeman¹
- 10 1 Weizmann Institute of Science, Israel
- 11 2 Meir Medical Center; Tel Aviv University, School of Medicine, Israel

12 Abstract

- 13 **Background** Fetal growth restriction (FGR) is a pregnancy complication in which a newborn
- 14 fails to achieve its growth potential, increasing the risk of perinatal morbidity and mortality.
- 15 Chronic maternal gestational hypoxia, as well as placental insufficiency are associated with
- 16 increased FGR incidence; however, the molecular mechanisms underlying FGR remain unknown.
- 17 Methods In a case control study of murine and human control and FGR placentae, we
- 18 implied MR imaging, IHC and metabolomics to assess the levels of BPGM and 2,3 BPG to
- elucidate the impact of maternal gestational hypoxia, and the molecular mechanisms underlyinghuman FGR.
- 21 Results We show that murine acute and chronic gestational hypoxia recapitulates FGR 22 phenotype and affects placental structure and morphology. Gestational hypoxia decreased 23 labyrinth area, increased the incidence of red blood cells (RBCs) in the labyrinth while expanding the placental spiral arteries (SpA) diameter. Hypoxic placentae exhibited higher hemoglobin-24 25 oxygen affinity compared to the control. Placental abundance of bisphosphoglycerate mutase 26 (BPGM) was upregulated in the syncytiotrophoblast and spiral artery trophoblast cells (SpA 27 TGCs) in the murine gestational hypoxia groups compared to the control. In contrast, human FGR placentae exhibited reduced BPGM levels in the syncytiotrophoblast layer compared to 28 29 placentae from healthy uncomplicated pregnancies. Levels of 2,3 BPG, the product of BPGM, 30 were lower in cord serum of human FGR placentae compared to control. Polar expression of

31 BPGM, was found in both human and mouse placentae syncytiotrophoblast, with higher

32 expression facing the maternal circulation. Moreover, in the murine SpA TGCs expression of

33 BPGM was concentrated exclusively in the apical cell side, in direct proximity to the maternal

34 circulation.

35 **Conclusions** This study suggests a possible involvement of placental BPGM in maternal-fetal 36 oxygen transfer, and in the pathophysiology of FGR.

37 **Funding** This work was supported by the Weizmann - Ichilov (Tel Aviv Sourasky Medical

38 Center) Collaborative Grant in Biomedical Research (to MN) and by the Israel Science

39 Foundation KillCorona grant 3777/19 (to MN, MK).

- 40
- 41

42 Introduction

The placenta is a transient organ, crucial for the growth and development of the fetus during 43 gestation¹². The placenta provides the interface between the maternal and fetal circulation, 44 mediating gas and metabolic exchange along with fetal waste disposal³. Abnormalities in 45 placental growth, structure, and function are associated with gestational complications such as 46 fetal growth restriction (FGR)⁴⁵, which is defined as the failure of the fetus to reach its growth 47 potential⁶. The clinical definition of FGR is fetal weight below the 10th percentile of predicted 48 fetal weight for gestational age⁷. FGR affects approximately 10-15% of pregnancies, increasing 49 the risk of perinatal morbidity and mortality⁶. Long-term complications of FGR include poor 50 postnatal development and are associated with multiple adverse health outcomes including 51 respiratory, metabolic and cardiovascular deficits⁸⁹. 52

There are numerous etiologies for FGR, some of which are related to fetal genetic aberrations or malformations, others related to placental or umbilical malformation, or also to maternal infections or diseases. Maternal anemia, smoking, high altitude residency, as well as placental and umbilical cord anomalies, are all associated with restricted placental and fetal oxygen availability¹⁰. Interestingly, about 40 percent of all FGR cases are idiopathic¹¹, with no identifiable cause, which might hint on possible biological pre disposition factors that contribute to FGR development by creating an hypoxic placental or embryo environment. However, the


60 molecular mechanisms that provoke and contribute to this pregnancy complication have yet to

61 be elucidated.

One of the key placental functions is the transfer of oxygen from the mother to the fetus¹², and 62 inefficient oxygen transport and availability is detrimental for placental and embryonic 63 development¹³¹⁴. Late-gestation hypoxia results in utero-placental vascular adaptations, such as 64 65 capillary expansion, thinning of the inter-haemal membrane and increased radial artery diameters¹⁵. Moreover, there is substantial evidence that late-gestation exposure to hypoxic 66 environment alters placental structure and functionality¹⁶¹⁷. *In-vitro* studies on human placental 67 samples under acute reduction of oxygen tension induced direct placental vasoconstriction¹⁸. 68 Placental oxygen transport depends on Hemoglobin (Hb), which is responsible for carrying and 69 mediating oxygen transfer in mammalian organisms¹⁹. BOLD contrast MR imaging is a powerful 70 tool that utilizes hemoglobin as an endogenous reporter molecule to assess oxygen-hemoglobin 71 affinity²⁰. Previous MR studies have shown altered placental oxygen-Hb affinity following 72 exposure to hypoxia²¹. However, limited information is available on how placental structure and 73 74 function is altered in chronic gestational hypoxia that commences at the onset of gestation.

The most significant allosteric effectors of Hb are organic phosphates, specifically 2,3 BPG, 75 76 which is produced by the BPGM enzyme in a unique side reaction of glycolysis, known as the Luebering-Rapoport pathway²². 2,3 BPG plays a key role in delivering O_2 to tissues by binding to 77 and stabilizing deoxy-hemoglobin, thus leading to the release of oxygen from the Hb unit²³²⁴. 78 79 During gestation, fetal hemoglobin (HbF) is the dominant form of Hb present in the fetus, comprised of α and γ subunits²⁵. During late gestation, the γ subunit is gradually replaced by the 80 adult β subunit²⁵. HbF has a higher affinity to oxygen compared to the adult Hb, caused by a 81 structural difference, which leads to a weakened ability to bind 2,3 BPG²⁶²⁷²⁸. The transfer of 82 oxygen from maternal to fetal Hb is facilitated by the higher affinity of maternal Hb to 2,3 BPG²⁴. 83 84 Remarkably, BPGM expression is specifically restricted to erythrocytes and the 85 syncytiotrophoblast of the placenta, a multinucleated layer that mediates transport of oxygen and nutrients from the mother to the fetus²⁹. In a study that used $igf2^{+/-}$ knockout mice as a 86 model of FGR, BPGM expression in the placental labyrinth was lower compared to wild type 87 placentae³⁰. However, scarce information is available on the role of this enzyme during 88 89 gestation.

- We report here that placental BPGM expression pattern is consistent with a role in adaptation of the placenta to gestational hypoxia, facilitating the transfer of oxygen from maternal to fetal circulation. Here we show that gestational hypoxia augments placental BPGM expression in mice, while in human FGR placentae of unknown etiology BPGM expression is suppressed.
- 102 Graphical abstract




109 Gestational Hypoxia Affects Maternal Hematological Parameters and Recapitulates FGR

110 Phenotype

Maternal hypoxia during pregnancy increases the risk of FGR ³¹³². To gain an understanding of 111 112 BPGM contribution to placental development and functionality following maternal hypoxia, we 113 established a murine model of acute and chronic gestational hypoxia. Increased erythropoiesis is the best-known physiological response to chronic hypoxia³³. Exposure to chronic hypoxia during 114 gestation significantly elevated maternal blood hematocrit and Hb levels (by 4.9±1.62 %PCV, 115 116 P=0.0243 and by 1.693±0.54 g/DL, P=0.0217 respectively, Figure 1 A, B) relative to the control 117 group. Both acute and chronic gestational hypoxia resulted in a significant increase in blood 118 acidity, presented by a decrease in pH values (P=0.0032 acute hypoxia versus control, P=0.0462 119 chronic hypoxia versus control, Figure 1 C).

120 Gestational acute and chronic hypoxia did not affect litter size (Figure 1 D). Thereafter, the 121 effect of gestational hypoxia on placental and fetal weight was assessed. A significant decrease 122 in placental weight was observed in both gestational hypoxia groups and in fetuses of the 123 chronic hypoxia group (acute hypoxia placentae by 15.03±4.2 mg, P=0.0068,; chronic hypoxia 124 placentae by 11.84±4.06 mg, P=0.0258 and fetuses by 50.24±18.11 mg, P=0.0343, Figure 1 E- G) 125 when compared to the control group. To further examine the weight differences, the percent of 126 small, average or large for gestational age (SGA, AGA and LGA respectively) fetuses and 127 placentae were compared to the control group. The results show that in the acute hypoxia 128 group 45% of the fetuses are SGA and only 2% LGA, whereas in the chronic hypoxia group 50% 129 of the fetuses are SGA and only 5% LGA (Figure 1 H). Furthermore, the placentae exhibited a 130 similar phenotype, where in the acute hypoxia group 35% of the placentae are SGA and none 131 were LGA, whereas in the chronic hypoxia group 21% of the placentae were SGA and only 1.6% 132 LGA (Figure 2 I).

133



134

Figure 1. Gestational hypoxia elevates maternal hemoglobin, hematocrit and blood acidity, 135 and recapitulates FGR phenotype. (A-B) Graphs showing hematocrit and hemoglobin levels in 136 maternal venous blood. (C) Graph shows pH levels in maternal venous blood. (D-F) Graphs 137 138 showing litter size, fetal weight and placental weight. (G) Representative picture of fetuses and 139 placentae (E16.5) from control and gestational hypoxia groups. (H-I) Analysis of the percentage of small for gestational age (SGA, weight less than the 10th percentile) fetuses and placentae, 140 large for gestational age (LGA, weight greater than the 90th percentile) fetuses and placentae, 141 and appropriate for gestational age (AGA, weight between the 10th and 90th percentiles) fetuses 142 143 and placentae at E16.5. Scale bars: 1 cm. Data displayed as mean ± SD and are from 49-62 144 fetuses and placentae from 6-7 dams per group (8–9 conceptuses per litter used). Ordinary one-145 way ANOVA test was used for statistical analysis.

147 Gestational Hypoxia Alters Placental Morphology

148 To determine whether the gestational hypoxia leads to structural changes of the placenta, the 149 placental morphology, and particularly the labyrinth area were examined. The labyrinth area of 150 the chronic and gestational hypoxia-exposed mice was significantly smaller (P=0.0001 for the acute and P=0.0003 for the chronic hypoxia groups, Figure 2 A, B) compared to the control 151 152 group. Furthermore, the diameter of the placental spiral arteries (SpA) was enlarged in the 153 chronic hypoxia group (Figure 2 C, D, P=0.0420) as compared to the control. In addition, in both 154 acute and chronic hypoxia groups the density of RBCs in the labyrinth were significantly higher 155 (P=0.0008 for the acute and P=0.007 for the chronic hypoxia groups, Figure 2 E, F) compared to 156 the control.

157

158




Figure 2. Maternal hypoxia during gestation results in enlarged spiral arteries, increased RBC levels and decreased placental labyrinth area. (A, B) Placentae of hypoxic chamber groups have significantly smaller labyrinth area in comparison to the control group.(C, D, E, F) Placentae of hypoxic chamber groups display enlarged spiral arteries and increased RBC levels in the labyrinth. Scale bars: 40 μm. Data are from 3 control, 4 chronic hypoxia and 4 acute hypoxia dams, 5-7 placentae per dam and presented as mean ± SD values. Ordinary one-way ANOVA test was used for statistical analysis.

173 R2* Maps Reveals Maternal, But Not Placental or Fetal changes in deoxygenated hemoglobin

174 concentration

175 As shown above, gestational hypoxia alters placental structure. To determine whether and how 176 gestational hypoxia affects placental functionality, the pregnant dams (E16.5) were subjected to 177 hyperoxia-hypoxia challenge during ultra-high field (15.2T) MR imaging (Appendix, video 1, 2, 3). 178 R2* values were calculated at each oxygen challenge for the maternal aorta, vena cava and liver 179 (Figure 3 A-D, Appendix Figure S1), and for the placenta, embryo heart, liver and aorta (Figure 3 180 E-H). The maternal aorta R2* levels from the chronic hypoxia group were significantly higher 181 (P=0.0376, Figure 3 A) than in the control group, when subjected to $10\% O_2$. However, no 182 differences were observed in maternal liver and vena cava when compared to that of the 183 control group (Figure 4 B, D). Similarly, no differences were observed in the R2* of embryonic 184 tissues (aorta, heart and liver), nor in the placenta, when comparing the hypoxic groups to the 185 control (Figure 4 E-H). To better understand the signal distribution in the different placental 186 regions, the R2* maps of the placentae were further analyzed. Interestingly no significant differences in the spatial distribution of R2* were observed in the placentae of hypoxic and 187 188 control groups (Figure 3 J).

189

190




Figure 3. Effects of maternal hypoxia during gestation on R2* values following hyperoxia-193 194 hypoxia challenge. (A-H) Graphs show that hypoxic challenge results in elevation in R2* values 195 in maternal aortas of chronic hypoxia chamber group, while no differences are observed in the 196 respective placentae and fetuses. (I) Representative R2* images of control and hypoxic chamber 197 group show several fetuses and their placenta (P), heart (H) and liver (L). Scale bars: 0.5 cm. (J) 198 Representative R2* maps inside the placenta of control, acute hypoxia (AH) and chronic hypoxia (CH) chamber groups at E16.5 show distribution of R2* values following hyperoxia-hypoxia 199 200 challenge. Data are from 8 control, 6 acute hypoxia and 7 chronic hypoxia per dams presented 201 as mean ± SD values. R2* values of embryonic tissues and placentae are calculated as the 202 median per mother, 5-8 embryos per each mother. Ordinary one-way ANOVA test was used for 203 statistical analysis.

204

- 205
- 206

207

208 BPGM is Upregulated in Placental Cells Following Gestational Hypoxia

209 Our present findings revealed structural changes in placentae from hypoxic mothers, however 210 functional MRI experiments demonstrated that placental deoxyhemoglobin concentrations are 211 similar to the control group. BPGM expression was previously observed in human placental syncytiotrophoblast cells from healthy pregnancies²⁹. Therefore, we inspected the expression of 212 213 BPGM in the labyrinth of the gestational hypoxia FGR murine model compared to the control. 214 Significant differences were observed in the syncytiotrophoblast BPGM expression between the hypoxic and control placentae (Figure 4 A, C). Although BPGM expression has only been 215 216 reported in the syncytiotrophoblast, we also inspected the BPGM expression in other placental 217 cells that come in direct contact with maternal blood. BPGM expression was found also in the 218 spiral artery trophoblast cells (SpA TGCs), an expression that is upregulated following acute and 219 chronic maternal hypoxia (Figure 4 D); moreover, SpA TGCs BPGM expression was found to be 220 polar and concentrated in the apical cell side facing the arterial lumen (Figure 4 B).

221

222






Figure 4. Maternal hypoxia during gestation results in elevated placental BPGM expression 225 226 levels. (A,D) Representative images and quantification of BPGM expression in the placental 227 labyrinth at E16.5 of control and hypoxic chamber groups. Scale bars: 30 µm (B,C,E) Trophoblast 228 cells lining the arteries show an increase of BPGM expression in chronic hypoxia group. The 229 expression of BPGM is restricted to the apical trophoblast cell side facing the arterial lumen. 230 Scale bars: 30 μm (B), 10 μm (C). Data are from 3 control, 4 chronic hypoxia and 4 acute hypoxia 231 dams, 2-3 placentae per group and presented as mean ± SD values. Ordinary one-way ANOVA 232 test was used for statistical analysis.


- 233
- 234
- 235
- 236
- 237

238 BPGM expression is Downregulated in Human FGR placentae

239 An upregulation of syncytiotrophoblast and SpA TGCs BPGM levels was detected in the murine 240 gestational hypoxia placentae. Therefore, to determine whether BPGM expression is also 241 altered in human placental syncytiotrophoblast cells of pregnancies complicated by FGR, human 242 placentae from healthy and FGR-complicated third-trimester pregnancies were examined. 243 Seventeen samples collected from Meir and Wolfson Medical Centers were selected from 236 244 deliveries, following childbirth and classified into two groups: FGR complicated pregnancies and 245 matched control deliveries (Table 1 and Figure 5). Clinical characteristics and neonatal outcomes 246 are provided in Table 1. Clinical parameters did not differ among the groups, except for 247 birthweight, which was significantly lower in the FGR group, as compared with the control 248 (Unpaired t-test; P = 0.0004). A downregulation of syncytiotrophoblast cells BPGM levels was observed in the FGR placentae (Figure 6 C). No differences were observed in 2,3 BPG levels in 249 250 plasma analyzed by mass spectrometry (Figure 6 D, E). However, the results maternal 251 demonstrated a significant reduction of 2.3 BPG levels in cord plasma from FGR complicated 252 pregnancies (Figure 6 D, F).

253

254



255

Figure 5. Patient selection flow chart. 16 Pregnant women were recruited from the Meir and Wolfson Medical Centers.

259

Parameter	Control <i>n</i> =9	FGR <i>n</i> =7	P value	
Maternal age, mean ± SD, years	30.2 ± 5.6	29.14 ± 5.6	0.7291	
Gestational age, mean ± SD, weeks	38.2 ± 1	37.5 ± 0.6	0.1644	
Preterm delivery (<37), n (%)	0	0		
Pregravid BMI (kg/m²), mean ± SD	22.8 ± 4.5	27.1 ± 3.6	0.2598	
Gravidity, median (IQR)	2.3 (1.5)	2. (2)		
Parity, median (IQR)	1.2 (1.5)	1 (2)		
Maternal comorbidities, n (%)				
Hypertensive disorders	0	0		
Diabetes or gestational diabetes	1 (11)	1 (14)		
Asthma	0	0		
Thyroid disease	0	0		
Smoker	5	3		
Infant sex, n (%)				
Male	7 (77)	4 (57)		
Female	2 (23)	3 (43)		
Birthweight, mean ± SD, grams	3167 ± 494	2189.4 ± 189	***0.0004	
NICU, n (%)	0	1 (14)		

260

Table 1. Clinical parameters of women included in the study. Clinical parameters did not differ among the groups, except for birthweight, which was significantly lower in the FGR group (Unpaired *t*-test, *P*=0.0004).

264

265






Figure 6. Human FGR placentae exhibit lower BPGM and 2,3 BPG levels. (A, B) Representative
 images of BPGM expression in control and FGR placentae. Scale bars: 30 μm. (C) Graph
 representing intensity of BPGM expression in control and FGR placentae. (D-F) Levels of 2,3 BPG
 in maternal and cord serum of control and FGR placentae. Data are from 9 control and 7 FGR
 women and presented as mean ± SD values. Unpaired *t* test was used for statistical analysis.
 Discussion

274 Proper placental and fetal oxygenation is essential for a healthy pregnancy. Accordingly, maternal gestational hypoxia constitutes a risk factor for FGR incidence³⁴. However, the etiology 275 276 and molecular mechanism underlying idiopathic as well as maternal gestational hypoxia induced 277 FGR remains unclear. In order to elucidate on the mechanisms leading to FGR, this study 278 employed a murine FGR model based on maternal acute and chronic gestational hypoxia. 279 Hypoxia-induced FGR placentae displayed smaller labyrinth fraction, higher RBC content and 280 enlarged spiral arteries. However, in vivo functional MRI experiments in response to hypoxia-281 hyperoxia challenge are consistent with similar deoxyhemoglobin content in all groups. Oxygen 282 release under hypoxia might be regulated by 2,3BPG, as suggested by the BPGM expression in 283 the murine hypoxic placentae which was upregulated and concentrated in the cell side facing 284 the maternal circulation. Conversely, human FGR placentae of unknown etiology exhibited an 285 opposite phenotype, presenting lower BPGM expression and reduced level of 2.3 BPG in the 286 chord serum. This suggests that induction of placenta BPGM may be part of the hypoxic 287 adaptation response in the murine placenta; while suppression of BPGM may contribute to 288 placenta deficiency in the human FGR.

289 Intra-uterine hypoxia has adverse effects on placental and embryonic development. This study 290 shows a decreased placental and embryonal weight, and a reduction in the percent of AGA and 291 LGA placentae and fetuses in the gestational hypoxia groups, with no difference in litter size 292 between hypoxic and control groups. Moreover, the labyrinth area of hypoxic placentae was 293 significantly smaller, implying an improper placental development. Previous studies showed that 294 intermittent hypoxia increased placental weight and labyrinth size, while chronic gestational 295 hypoxia in mice leads to reduced litter size and had no effect on the labyrinth zone³⁵³⁶. These 296 contradictory results may be due to the different experimental setups employed in the 297 intermittent hypoxia model, and the differences in litter size of the chronic hypoxia model, 298 which might in turn affect placental size and development. Furthermore, the current study 299 demonstrated an increase in the diameter of placental SpA following gestational hypoxia. This 300 enlargement might serve as a compensational mechanism for the placental and labyrinthine size 301 reduction, by supplying higher volumes of blood to the placenta thereby increasing oxygen 302 content, tissue oxygenation and oxygen supply to the fetus. Previous studies have shown that 303 gestational hypoxia from mid-late gestation increased the diameter of radial arteries compared 304 to control¹⁵; however, no significant difference was observed in the spiral arteries, possibly due 305 to the late exposure to hypoxia. However, this study mimics adaptation to early gestational 306 hypoxia and early onset placental dysfunction leading to severe FGR and therefore, might serve307 as a better model for the human hypoxic-induced FGR.

308 MRI is an important tool for imaging changes in deoxyhemoglobin concentration in vivo. 309 Previous *in vivo* studies on non-treated pregnant mice obtained oxygen-hemoglobin dissociation curves in mid-late gestation placentae under hyperoxia - hypoxia challenge³⁷. Interestingly, in 310 311 the present study no significant differences were found in the R2* values between the hypoxic 312 and control placentae under hyperoxic, normoxic and hypoxic conditions. This result is 313 consistent with similar deoxyhemoglobin levels in the hypoxic and control placentae, despite the 314 upregulation of RBC levels in the hypoxic placentae. These results indicate that the partial 315 amount of HbO₂ is higher in the hypoxic placentae compared to the control, implying on the 316 ability of the placenta to maintain its oxygen levels albeit the maternal hypoxia.

317 In RBCs, the BPGM enzyme is responsible for the synthesis of 2,3 BPG, which induces the release 318 of oxygen from Hb in the mammalian organism. Remarkably, the expression of BPGM has been 319 reported in the human placental labyrinth²⁹, suggesting on its role in placental oxygen transfer. 320 This study shows for the first time the polar pattern of BPGM expression in both the murine and 321 human placental cells, amassing at the apical lumen, facing the maternal circulation. This polar 322 expression might increase the efficiency of oxygen sequestering from maternal blood by 323 reducing the distance between 2,3 BPG molecule and the maternal RBCs. Moreover, following 324 maternal intra-uterine hypoxia, the expression of murine placental BPGM is further upregulated, 325 suggesting a physiological role for placenta BPGM in the placental acclimatization to low oxygen 326 availability. Strikingly, attenuation in the expression of BPGM in FGR human placentae was 327 found when compared to the control. Moreover, 2,3 BPG levels in the cord serum of FGR 328 placentae were also decreased compared to control. This suggests that failure in induction of 329 placental BPGM and subsequently lower 2,3 BPG levels may contribute to the pathophysiology 330 of FGR. Remarkably, the same phenotype was observed in a murine FGR model of igf2+/-331 knockout mice, where labyrinthine BPGM expression was lower compared to control dams 30 . 332 This study demonstrates opposite BPGM expression patterns in mouse and human FGR, 333 suggesting that the murine FGR in our model originates in low maternal oxygen concentrations, 334 which are compensated by the placenta via upregulation of BPGM levels, while human FGR of 335 unknown etiology is related to a placental pathology that might include inadequate BPGM expression. During human gestation, the y hemoglobin subunit starts to decline around week 32 336

and β hemoglobin rises, switching from fetal to adult hemoglobin. Following this increase in HbA
in the fetus, it might be possible that placental BPGM and 2,3 BPG are also used by the fetus at
that stage, to mediate the release of oxygen to its organs. However, the question of how
placental 2,3 BPG might be transported to the nearby maternal RBCs needs to be addressed,
while a possible explanation would be a specific transport system.

In summary, we propose that placental BPGM provides an important mechanism for placental adaptation to oxygen transfer during the course of gestation. We suggest that placental BPGM sequesters oxygen from the maternal Hb, and facilitates oxygen diffusion from the maternal to the fetal circulation. These results offer a possible causative link between the expression of this enzyme and the development of an FGR. This novel molecular mechanism for the regulation of oxygen availability by the placenta might provide a better understanding of the FGR pathology and possibly pave the way toward development of novel therapies for FGR complications.

349

350 Materials and Methods

351 Animals

352 Female C57BL/6JOlaHsd mice (8-12 weeks old; Envigo, Jerusalem; n=28) were mated with 353 C57BL/6JOlaHsd male mice (Envigo, Jerusalem; n=8). Detection of a vaginal plug the following 354 day was considered embryonic day 0.5 (E0.5). At E0.5 or E11.5, the pregnant females were 355 randomly allocated to control (21% O_2 , n = 15) or hypoxia group (12.5% O_2 , acute hypoxia; n=6, 356 chronic hypoxia; n=7). Throughout the experiments, the animals were maintained in a 357 temperature-controlled room ($22 \pm 1^{\circ}$ C) on a 12h:12h light–dark cycle. Food and water was provided ad libitum and animal well-being was monitored daily. At E16.5 the pregnant females 358 359 were analyzed using high-field MRI under a respiration challenge of hyperoxia-to-hypoxia (40% 360 O₂, 20% O₂, 10% O₂). After MR imaging, the animals were sacrificed for tissue collection. All 361 experimental protocols were approved by the Institutional Animal Care and Use Committee 362 (IACUC) of the Weizmann Institute of Science, Protocol number: 07341021-2.

363 Establishment of Maternal Hypoxia Models

We applied two models of maternal hypoxia – acute and chronic. The pregnant mice were housed in a hypoxic chamber (VelO2x, Baker Ruskinn, Sanford, Maine, USA) from E11.5 (acute

366 hypoxia; n=6) or E0.5 (chronic hypoxia; n=7) until E16.5. On the first day in the hypoxic chamber, 367 maternal oxygen supply was gradually reduced from $21\%O_2$ to $12.5 \pm 0.2\% O_2$ by continuous 368 infusion of a nitrogen gas. The water contained in the expired gas was trapped using silica gel 369 beads (Merck, CAS #: 7631-86-9). A portable oxygen analyzer (PO₂-250, Lutron, Coopersburg, 370 Pennsylvania, United States) was used to monitor the oxygen concentration in the chamber. 371 Pregnant control females were housed in an identical chamber supplied with a constant $21\% \pm$ 372 0.2% O₂ concentration.

373 In Vivo MR Imaging

374 MR imaging examinations were performed at a 15.2T with an MR spectrometer (BioSpec 152/11 375 US/R; Bruker, Karlsruhe, Germany) equipped with a gradient-coil system capable of producing 376 pulsed gradients of 10 mT/cm in each of the three orthogonal directions. A quadrature volume 377 coil with a 35-mm inner diameter and an homogeneous radiofrequency field of 30 mm along the 378 axis of the magnetic field was used for both transmission and reception. Immediately prior to 379 MR imaging, the pregnant females were anesthetized with isoflurane (3% for induction; Piramal, 380 Mumbai, India) mixed with 2 L/min of 40% O_2 and 60% N_2 delivered into a closed induction 381 chamber. Once anesthetized, the animals were placed in a prone position in a head holder with 382 breathing gas mixed with isoflurane delivered through a tooth bar. Respiration rate and rectal 383 temperature were monitored using a monitoring and gating system (Model 1030-S-50; SA 384 Instruments, Stony Brook, NY). Respiration rate was maintained throughout the experimental 385 period at approximately 20-30 breaths per minute by adjusting the isoflurane level (1%–2% for 386 maintenance). Body temperature was maintained at 30±1°C (to reduce fetal movement) by 387 adjusting the temperature of a circulating water heating blanket placed above the animal.

388 MR Imaging Data Acquisition

Anatomic data to determine optimal animal positioning was acquired by using a short Gradient Recalled Echo (GRE) sequence with imaging slices acquired in three orthogonal planes. The animals were positioned to maximize the number of fetuses that could be viewed while still observing maternal liver. The duration of the MRI measurements at each oxygen level was approximately 20 min. After the O₂ concentration was reduced, a 2 minute interval was given before acquiring the next set of MRI images, allowing R2* stabilization. At each oxygen phase, the nitrogen level was adjusted to maintain a constant flow of inhaled gas. To determine R2*

values three Gradient Recalled Echo (GRE) acquisitions were performed with TE= 1.6 ms, 2.6 ms
and 3.6 ms. The parameters for these GRE measurements were as follows: 48 slices with slice
thickness of 0.4 mm with 0.1 mm inter-slice gap, field of view 4.2 X 3.3 cm², pulse flip angle 40°,
matrix size 280 x 220 (150 x 150 um² pixel size), 2 averages (motion averaging). Images were
acquired with fat suppression and RF spoiling. The excitation pulse was 0.5 ms (6400 Hz
bandwidth) and the acquisition bandwidth was 200 kHz. The slice order was interleaved. The
sequence was respiration triggered (per slice) with an approximate TR of 800 ms.

403 MR Imaging Data Analysis

Images were reconstructed by Paravision 6.0 (Bruker, Karlsruhe, Germany). The GRE images used for calculating R2*s were interpolated in Matlab (MathWorks, Natick, Massachusetts, USA) to 75X75 um² pixel size. Regions of Interest (ROIs) were manually marked with ImageJ (U. S. National Institutes of Health, Bethesda, Maryland, USA). Subsequently, using custom written scripts all ROIs and images were imported into Matlab and the R2* for each O₂ level was determined by fitting the changes in the median signal intensity of each ROI to a single exponential decay [Eq 1]:

411 $Int = Int_0 \cdot e^{-R_2^* \cdot TE}$ [Equation 1]

412 **Tissue collection**

413 Mouse placentae samples: After MR Imaging of the animals, maternal blood was collected from 414 the submandibular vein, followed by cervical dislocation. Maternal hematocrit and Hb levels 415 were determined using i-STAT CG8+ cartridge (Abbott, Cat. No. ABAXIS-600-9001-10, Chicago, 416 Illinois, USA). Uterine tissues were immersed in PBS to count the number of fetuses and 417 resorptions. Fetuses and placentae were immediately removed and weighed, following by fixation in 4% paraformaldehyde. Grade of embryonic and placental weight was classified as SGA 418 (weight less than the 10th percentile), large for gestational age (LGA, weight greater than the 419 90th percentile), and appropriate for gestational age (AGA, weight between the 10th and 90th 420 421 percentiles).

422 Human placentae samples: The study was approved by the Meir and Wolfson Medical Center 423 IRB Local Committee (Protocols: # 0147-20 MMC and #185-19-WOMC). Written informed 424 consent was obtained from all participants prior to delivery. Placentae from 9 healthy 425 uncomplicated pregnancies and from 7 pregnancies complicated by fetal growth restriction

426 (FGR) were collected immediately after elective cesarean deliveries. Two biopsies were taken
427 from each placenta, one from a peripheral and one from a central lobule. The biopsied material
428 (~ 1 cm³) was immediately fixed in formalin. FGR birth weight standards were based on the
429 Dollberg curve.

Human Serum: Maternal and cord serum samples were collected from the enrolled patients prior to delivery, and from the umbilical cord just following delivery. The umbilical cord was wiped clean and blood was drawn from the vein. Blood samples were centrifuged (1000g, 10 minutes at room temperature), and serum aliquots were stored at -80°C in dedicated tubes for analyses at the Weizmann Institute.

435 Immunohistochemistry and Microscopy

Fixed murine and human placentae were processed and embedded in paraffin. Representative 5
 μm sections were taken from each tissue and used for immunohistochemistry (IHC).

438 All slides were dewaxed and rehydrated in xylene and a series of ethanol washes. IHC staining 439 involved antigen retrieval in a pressure cooker using citrate buffer (pH=6) and blocking of non-440 specific binding with 20% NHS and 0.2% Triton in PBS. Slides were incubated with polyclonal rabbit primary anti-BPGM antibody (1:200, Sigma-Aldrich, Cat. No. HPA016493, 441 442 RRID:AB 1845414), followed by incubation with an HRP anti-Rabbit secondary antibody (1:100, 443 Jackson ImmunoResearch Labs, Cat# 111-035-003, RRID:AB 2313567) followed by Opal 690 444 (1:500, Akoya Biosciences, Cat. No. FP1497001KT). Negative controls for each immunostaining 445 were incubated with secondary antibody only.

Images were captured using Nikon Eclipse Ti2_E microscope, Yokogawa CSU W1 spinning disk,
photometrics Prime 25B camera with NIS elements AR 5.11.01 64bit software.

448 Placental Morphological Analysis

For the assessment of placental labyrinth size, fractional area expressing both BPGM and containing fetal RBCs of each placenta was computed *via* use of the color thresholding and area fraction tools in ImageJ. Approximately 10 measurements were made per each placenta. Spiral arteries diameter was measured manually using ImageJ, namely, for each spiral artery 5-6 measurements were made. For the assessment of RBC levels in the labyrinth, thresholding of the RBC auto fluorescence signal was employed. Quantification of mouse placental BPGM in the 455 labyrinth was performed using color thresholding in ImageJ, 10 identical measurements were 456 done for each placenta, 500x500 µm each. For the assessment of BPGM in the SpA TGCs, regions 457 of interest were drawn manually implying the same thickness from the inner vessel border 458 followed by color thresholding in ImageJ. We quantified human BPGM expression level by 459 creating a binned intensity histogram of all the pixels expressing BPGM signal above a minimal background value (of 1000), in a single slice of each sample using Fiji Macro³⁸. As red blood cells 460 461 (RBC) have high auto fluorescence in all channels, we discarded RBC regions them prior BPGM quantification. This is done in Imaris (Oxford company) by creating Surface object for RBC 462 463 (default parameters, automated absolute intensity threshold), and using it to create new PBGM 464 channel in which the values in the RBC regions are set to zero.

465 LC–MS/MS measurement of 2,3-BPG

466 Ten-uL aliquots of plasma were extracted with 80uL of extraction buffer (10mM ammonium acetate/5mM ammonium bicarbonate, pH 7.7 and methanol in ratio 1:3 by volume), and 10uL 467 468 of methionine sulfone (lug/mL in water) was added as internal standard. The mixture was 469 vortexed, incubated at 10°C for 10min, then centrifuged (21,000g for 10min). The supernatant 470 was collected for consequent LC–MS/MS analysis. The LC–MS/MS instrument consisting of an 471 Acquity I-class UPLC system (Waters) and Xevo TQ-S triple guadrupole mass spectrometer 472 (Waters), equipped with an electrospray ion source, was used for analysis of 2,3-BPG. MassLynx 473 and TargetLynx software (v.4.1, Waters) were applied for the acquisition and analysis of data. 474 Chromatographic separation was performed on a 150mm × 2.1mm internal diameter, 1.7-μm 475 BEH Z-HILIC column (Waters Atlantis Premier) with mobile phases A (20mM ammonium 476 carbonate, pH 9.25/acetonitrile, 80/20 by volume) and B (acetonitrile) at a flow rate of 477 0.4ml min-1 and column temperature of 25°C. A gradient was used as follows: for 0-0.8min a 478 linear decrease from 80 to 35%B, for 0.8–5.6min further decrease to 25%B, for 5.6–6.0min hold 479 on 25%B, then for 6.0-6.4min back to 80%B, and equilibration at 80%B for 2.6min. Samples kept 480 at 8°C were automatically injected in a volume of 5μ l. 2,3-BPG concentration was calculated 481 using a standard curve, ranging from 0.1–100µg ml-1. For MS detection MRM transitions 265.0>78.8, 265.0>167.0 m/z (ESI -) were applied in case of 2,3-BPG, with collision energies 31 482 483 and 12eV, respectively. Internal standard was detected using MRM 182.1>56.0 m/z (ESI +), with 484 collision energy 18eV.

485 Statistical Analysis

Ordinary one-way Anova test was applied for the comparison between the three pregnant females groups (control, acute and chronic hypoxia). Litter means were used for statistical analysis of fetal and placental weights. Unpaired *t*-test was used for the analysis of the IF images of FGR and control human placentae. The data were considered to indicate a significant difference when *P* values were less than 0.05. All results are represented as the mean ± SD. Statistical analysis was performed using Graphpad Prism 6 (GraphPad Software, San Diego, USA) for Windows.

493 Acknowledgements

494 This work was supported by the Weizmann - Ichilov (Tel Aviv Sourasky Medical Center) 495 Collaborative Grant in Biomedical Research (to MN) and by the Israel Science Foundation 496 KillCorona grant 3777/19 (to MN, MK). Graphical abstract was created with BioRender.com.

497 Author contributions and disclosures

- 498 S.S., N.D., M.N. designed the research, S.S., T.H., L.F.A, L.B.M., A.B., T.M., performed the
- 499 research, L.F.A., R.P.M., M.K., T.B.S, contributed vital new reagents or analytical tools, S.S, T.H.,
- 500 O.G., analyzed the data, and S.S., N.D. and M.N. wrote the paper.

501 Conflict-of-Interest

502 The authors declare no conflicts of interest.

503 Data availability

All data are available, without restriction, upon request.

505

506

- 507
- 508

- 510
- 511

512 References

- 513 1. Gude NM, Roberts CT, Kalionis B, King RG. Growth and function of the normal human 514 placenta. *Thromb Res.* 2004;114(5-6 SPEC. ISS.):397-407.
- 515 doi:10.1016/j.thromres.2004.06.038
- 516
 2.
 Garnica AD, Chan WY. The role of the placenta in fetal nutrition and growth. J Am Coll

 517
 Nutr. 1996;15(3):206-222. doi:10.1080/07315724.1996.10718591
- 5183.Burton GJ, Fowden AL. The placenta: A multifaceted, transient organ. Philos Trans R Soc B519Biol Sci. 2015;370(1663). doi:10.1098/RSTB.2014.0066
- Woods L, Perez-Garcia V, Hemberger M. Regulation of Placental Development and Its
 Impact on Fetal Growth—New Insights From Mouse Models. *Front Endocrinol* (*Lausanne*). Published online 2018. doi:10.3389/fendo.2018.00570
- Sun C, Groom KM, Oyston C, Chamley LW, Clark AR, James JL. The placenta in fetal growth restriction: What is going wrong? *Placenta*. 2020;96:10-18.
 doi:10.1016/J.PLACENTA.2020.05.003
- 5266.Romo A, Carceller R, Tobajas J. Intrauterine Growth Retardation (IUGR): Epidemiology527and Etiology. Abstr Ref Ped Endocrinol Rev. 2008;6:pp.
- Lausman A, Kingdom J, Gagnon R, et al. Intrauterine growth restriction: Screening,
 diagnosis, and management. *J Obstet Gynaecol Canada*. 2013;35(8):749-757.
 doi:10.1016/S1701-2163(15)30866-5
- 5318.Sharma D, Shastri S, Sharma P. Intrauterine Growth Restriction: Antenatal and Postnatal532Aspects. Clin Med Insights Pediatr. 2016;10:67. doi:10.4137/CMPED.S40070
- 533 9. Von Beckerath AK, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P. Perinatal
 534 complications and long-term neurodevelopmental outcome of infants with intrauterine
 535 growth restriction. *Am J Obstet Gynecol*. 2013;208(2):130.e1-130.e6.
 536 doi:10.1016/J.AJOG.2012.11.014
- 537 10. Chew LC, Verma RP. Fetal Growth Restriction. In: StatPearls. Treasure Island (FL):
 538 StatPearls Publishing; June 11, 2022.
- 53911.Ghidini A. Idiopathic fetal growth restriction: A pathophysiologic approach. Obstet540Gynecol Surv. 1996;51(6):376-382. doi:10.1097/00006254-199606000-00023
- 54112.Burton GJ. Oxygen, the Janus gas; its effects on human placental development and542function. In: Journal of Anatomy. ; 2009. doi:10.1111/j.1469-7580.2008.00978.x
- 543 13. Carter AM. Placental gas exchange and the oxygen supply to the fetus. *Compr Physiol*.
 544 Published online 2015. doi:10.1002/cphy.c140073
- I4. Zhou J, Xiao D, Hu Y, et al. Gestational hypoxia induces preeclampsia-like
 symptoms via heightened endothelin-1 signaling in pregnant rats. *Hypertension*.
 2013;62(3):599-607. doi:10.1161/HYPERTENSIONAHA.113.01449
- 54815.Cahill LS, Rennie MY, Hoggarth J, et al. Feto- and utero-placental vascular adaptations to549chronic maternal hypoxia in the mouse. J Physiol. 2018;596(15):3285-3297.

550 doi:10.1113/JP274845

551	16.	Higgins JS, Vaughan OR, Fernandez de Liger E, Fowden AL, Sferruzzi-Perri AN. Placental
552		phenotype and resource allocation to fetal growth are modified by the timing and degree
553		of hypoxia during mouse pregnancy. <i>J Physiol</i> . 2016;594(5):1341-1356.
554		doi:10.1113/JP271057


- Tomlinson TM, Garbow JR, Anderson JR, Engelbach JA, Nelson DM, Sadovsky Y. Magnetic
 resonance imaging of hypoxic injury to the murine placenta. Am J Physiol Regul Integr
 Comp Physiol. 2010;298(2):312-319. doi:10.1152/ajpregu.00425.2009
- Howard RB, Hosokawa T, Maguire MH. Hypoxia-induced fetoplacental vasoconstriction in
 perfused human placental cotyledons. *Am J Obstet Gynecol*. 1987;157(5):1261-1266.
 doi:10.1016/S0002-9378(87)80307-1
- 561 19. Mairbäurl H, Weber RE. Oxygen Transport by Hemoglobin. Published online 2012.
 562 doi:10.1002/cphy.c080113
- 56320.Avni R, Neeman M, Garbow JR. Functional MRI of the placenta From rodents to564humans. Placenta. 2015;36(6):615-622. doi:10.1016/J.PLACENTA.2015.04.003
- Avni R, Golani O, Akselrod-Ballin A, et al. MR Imaging–derived Oxygen-Hemoglobin
 Dissociation Curves and Fetal-Placental Oxygen-Hemoglobin Affinities. *Radiology*.
 2016;280(1):68-77. doi:10.1148/radiol.2015150721
- Sasaki R, Ikura K, Narita H, Yanagawa S ichi, Chiba H. 2,3-bisphosphoglycerate in
 erythroid cells. *Trends Biochem Sci*. 1982;7(4):140-142. doi:10.1016/09680004(82)90205-5
- 571 23. Mulquiney PJ, Kuchel PW. Model of 2,3-bisphosphoglycerate metabolism in the human
 572 erythrocyte based on detailed enzyme kinetic equations: equations and parameter
 573 refinement. Biochem J. 1999;342 Pt 3(Pt 3):581-596.
- 574 24. Steinberg MH, Benz EJ, Adewoye AH, Ebert BL. Pathobiology of the Human Erythrocyte
 575 and Its Hemoglobins. *Hematol Basic Princ Pract*. Published online 2018:447-457.
 576 doi:10.1016/B978-0-323-35762-3.00033-0
- 577 25. Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new 578 therapies for the-globin disorders. Published online 2012. doi:10.1182/blood
- 579 26. Bauer C, Ludwig I, Ludwig M. Different effects of 2.3 diphosphoglycerate and adenosine
 580 triphosphate on the oxygen affinity of adult and foetal human haemoglobin. *Life Sci*.
 581 1968;7(23):1339-1343. doi:10.1016/0024-3205(68)90249-X
- 582 27. Frier JA, Perutz MF. Structure of human foetal deoxyhaemoglobin. *J Mol Biol.*583 1977;112(1):97-112. doi:10.1016/S0022-2836(77)80158-7
- Adachi K, Konitzer P, Pang J, Reddy KS, Surrey S. Amino Acids Responsible for Decreased
 3-Biphosphoglycerate Binding to Fetal Hemoglobin. *Blood*. 1997;90(8):2916-2920.
 doi:10.1182/BLOOD.V90.8.2916
- 587 29. Pritlove DC, Gu M, Boyd CAR, Randeva HS, Vatish M. Novel Placental Expression of 2,3588 Bisphosphoglycerate Mutase. *Placenta*. 2006;27(8):924-927.

589	doi:10.1016/j.placenta.2005.08.010
505	doi:10.1010/j.placenta.2005.00.010

- Gu M, Pritlove DC, Boyd CAR, Vatish M. Placental Expression of 2,3 Bisphosphoglycerate
 Mutase in IGF-II Knock out Mouse: Correlation of Circulating Maternal 2,3
 Bisphosphoglycerate and Fetal Growth. *Placenta*. 2009;30(10):919-922.
 doi:10.1016/j.placenta.2009.08.005
- 59431.Keyes LE, Armaza JF, Niermeyer S, Vargas E, Young DA, Moore LG. Intrauterine Growth595Restriction, Preeclampsia, and Intrauterine Mortality at High Altitude in Bolivia. *Pediatr*596*Res 2003 541*. 2003;54(1):20-25. doi:10.1203/01.pdr.0000069846.64389.dc
- 32. Jang EA, Longo LD, Goyal R. Antenatal maternal hypoxia: Criterion for fetal growth
 restriction in rodents. *Front Physiol*. 2015;6(MAY):176.
 doi:10.3389/FPHYS.2015.00176/BIBTEX
- 60033.Faura J, Ramos J, Reynafarje C, English E, Finne P, Finch CA. Effect of Altitude on601Erythropoiesis. *Blood*. 1969;33(5):668-676. doi:10.1182/BLOOD.V33.5.668.668
- Bucsay CA, Goyal R, Pearce WJ, Wilson S, Hu XQ, Zhang L. Gestational hypoxia and
 developmental plasticity. Physiol Rev. 2018;98(3):1241-1334. doi:
 10.1152/physrev.00043.2017
- Matheson H, Veerbeek JHW, Charnock-Jones DS, Burton GJ, Yung HW. Morphological
 and molecular changes in the murine placenta exposed to normobaric hypoxia
 throughout pregnancy. *J Physiol*. 2016;594(5):1371-1388. doi:10.1113/JP271073
- 60836.Badran M, Abuyassin B, Ayas N, Laher I. Intermittent hypoxia impairs uterine artery609function in pregnant mice. J Physiol. 2019;597(10):2639-2650. doi:10.1113/JP277775
- Avni R, Golani O, Akselrod-Ballin A, et al. MR Imaging–derived Oxygen-Hemoglobin
 Dissociation Curves and Fetal-Placental Oxygen-Hemoglobin Affinities. *Radiology*.
 2016;000(0):150721. doi:10.1148/radiol.2015150721
- 613 38. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: An open-source platform for biological-614 image analysis. *Nat Methods*. 2012;9(7):676-682. doi:10.1038/NMETH.2019
- 615
- 616
- 617
- 618
- 619
- 620
- 621
- 622
- 672
- 623
- 624

625 Supplementary





627


Figure S1. Effects of maternal hypoxia during gestation on R2* values following hyperoxia hypoxia challenge. (A) Representative R2* images of control and hypoxic chamber group show
 several dams and their liver (L), aorta (A) and vena cava (V). Scale bars: 0.5 cm.

631

632 MR imaging of mother, embryos and placentae

- 633 **Video 1, 2, 3:** Representative MRI scan videos of control. acute and chronic hypoxia dams
- 634 respectively.







25


55

Α.





C.



Acute

Hypoxia


Control


Fetus


Placenta


Chronic


Hypoxia
























F.




Α.











Mother Serum 2,3 BPG (ug/ml)




Chronic Hypoxia





Control




40% O₂









20% O₂

.

10% O₂